Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (November 2023)
8 slides from Oragenics's investor presentation, Nov 20, 2023
Slide 1: Corporate Presentation
Corporate Presentation
Slide 2: Forward-Looking Statements
2 rdiLooking Statements This communication contains “forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to successfully close the Odyss
Slide 3: At Oragenics, Nasal Drug Delivery is our Future
At-Oragenics, Nasal Drug Delivery is our Future The global nasal drug delivery technology market is projected to grow to $112B by 2030 Why? New technologies are emerging that leverage the nasal cavity’s ability to enhance drug bioavailability and to lower systemic exposure. This is good news for pat
Slide 4: Advantages of intranasal drug delivery
ges TD Over the past 10 years, interest in intranasal drug delivery in pharmaceutical Research & Development has increased Nasal delivery offers many advantages over standard systemic delivery systems, such as its non-invasive character, a fast onset of action and in many cases reduced side effects
Slide 5: Areas of Focus – present and future
” i of Focus — present and { The acquisition of assets from Odyssey Health, Inc., if successful, is anticipated to build on our expertise in intranasal platforms and expand our portfolio into more areas of unmet medical need oday: Atte
Slide 6: Agreement to acquire Odyssey Health neurological assets
* On October 5, 2023, Oragenics and Odyssey Health, Inc., entered into a definitive agreement to acquire assets related to Odyssey’s proprietary neurological drug therapies * These assets include Odyssey’s proprietary formulation and nasal delivery system as well as drug candidates for treating conc
Slide 7: Proprietary powder formulation and intranasal administration for ONP-002
Proprietary powder formulation and intranasal administration allows rapid and direct accessibility to the brain This asset (called ONP-002) is intended to treat concussion * Allows patients to blow into device which closes the soft palate eliminating the flow of drug to the lungs or esophagus * Mini
Slide 8: For More Information
Blvd., Suite 125 genics.com _For More Information Corpor Investors: “Yanet.-Huffman Tirth T. Patel Chief incial Officer ‘ LHA Investor Relations 813.286.7900 ext. 246 | jhuffman@oragenics.com 212.201.6614 | tpatel@Ihai.com’, a NYSE American: OGEN